Share on LinkedInShare on LinkedIn

ARTICLE · 14 NOVEMBER 2020

Alumni News: Q4 2020

Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP
Contributor
Herbert Smith Freehills Kramer LLP

Herbert Smith Freehills Kramer LLP

We have one of the largest Southeast Asia international law practices, working across the region...

View firm profile
Explore more from Herbert Smith Freehills Kramer LLP

Kramer Levin Collaborates With NYC Business Solutions to Launch Virtual Clinic for Small Businesses.

United StatesStrategy
Ann Kalodis
Ann Kalodis
Author LinkedIn connections

In This Issue:

  • In Memoriam: Mayer Greenberg
  • New Partner Hires
  • Firm News
  • Kramer Levin Establishes the Racial Justice Initiative
    • Kramer Levin Collaborates With NYC Business Solutions to Launch Virtual Clinic for Small Businesses
    • The Election
    • Kramer Levin's Veterans Assistance Project
  • Pro Bono News/Initiatives/Events
    • Supporting LGBTQ+ and Abortion Rights
    • Standing Up for Victims and Against Gun Violence
  • Wellness Resources
  • Follow Kramer Levin on Social Media
  • Recognitions
  • Upcoming Events

View Alumni News: Q4 2020.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters

Read more about

See more popular content from

Article

Contract Lifecycle Management And Why Legal Teams Need It

Contract lifecycle management has become the most widely adopted legal technology tool in corporate legal departments, addressing fundamental challenges around contract visibility, workflow automation, and risk management. Legal operations expert Jeff Reisner breaks down the CLM landscape, implementation considerations, and why this technology has emerged as the foundational piece most legal teams tackle first when modernizing their operations.
United StatesStrategy
Axiom
Axiom
Article

Ankura CTIX FLASH Update – September 22, 2026

This collection of insights from Ankura explores critical challenges facing multiple industries in 2026, from cybersecurity threats targeting AI assistants to the evolving landscape of freight capacity, cryptocurrency enforcement, and healthcare compliance. The articles examine how organizations navigate regulatory complexity, operational constraints, and emerging risks across financial services, logistics, healthcare, and technology sectors.
United StatesStrategy
Ankura Consulting Group LLC
Ankura Consulting Group LLC
Article

California SB 574 Would Bar Attorneys From Delegating The Practice Of Law To Generative AI

California Senate Bill 574 proposes a groundbreaking statutory framework that would prohibit attorneys from delegating legal practice to generative artificial intelligence, while imposing disclosure requirements and verification standards across litigation, arbitration, and court filings. The legislation raises fundamental questions about how traditional definitions of "the practice of law" apply to AI-augmented legal work, from document review to contract analysis. If signed by Governor Newsom, California
United StatesStrategy
A&O Shearman
A&O Shearman
Article

TMT Companies Should Prepare For Post-Midterm Congressional Scrutiny – No Matter Who Wins

The 2026 midterms could fundamentally alter congressional oversight of telecommunications, media, and technology companies. With Democrats signaling aggressive investigations into affordability, corporate pricing, and regulatory favoritism, and Republicans continuing probes into government influence over content moderation, TMT sector stakeholders face heightened scrutiny regardless of which party controls Congress. This analysis examines the key oversight risks companies should anticipate and the strategic
United StatesStrategy
Wiley Rein
Wiley Rein
Article

2026 Sees China's Biotech Scene Continuing Its Ascent – But Could US Developments Mean Clouds On The Horizon?

In recent years, China's biotech scene has risen in prominence with its innovative R&D and promising pipelines commanding big pharma's attention. In this blog, we take a look at this trend, which sees China-related deals and investment continuing to flow, as well as the recent developments in the US, with draft legislation being proposed that seeks to impose restrictions which would impact transactions between US pharma companies and Chinese biotechs. 
GlobalFood, Drugs, Healthcare, Life Sciences
Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP